Every few months, something changes in the fine print of Medicare, and millions of older Americans learn about it when the bill arrives. The Trump administration will end a key subsidy for Medicare Part D prescription drug plans starting in 2027, a move that could result in higher premiums for millions of seniors and disabled Americans. The announcement landed on a Tuesday in late July 2026, posted first on social media by the administrator of the Centers for Medicare & Medicaid Services, and the implications are still being calculated by insurers, policy experts, and the roughly 25 million people directly affected.
The dollar amounts being discussed – a potential increase of $10, maybe $20 a month – might sound modest in isolation. For someone on a fixed income managing multiple prescriptions, that math looks different. A $20 monthly increase is $240 a year, added to a budget that already has very little give.
What the Part D Premium Stabilization Demonstration Actually Was
Medicare Part D is optional prescription drug coverage offered by private insurance companies to help people with Medicare pay for brand-name and generic medications. It is available as a stand-alone plan to add to Original Medicare or as part of a bundled Medicare Advantage plan. The program has been part of the Medicare landscape since 2006.
The Inflation Reduction Act of 2022 restructured the benefit in ways that had real consequences for how insurers priced their plans. Under the Inflation Reduction Act of 2022, Medicare patients’ out-of-pocket drug spending was capped at $2,000 starting in 2025, and it changed the way insurers pay for drugs. Seniors would pay less at the pharmacy counter and have easier access to expensive prescription drugs, but insurers would be on the hook for more of the bill. That structural shift was good for enrollees’ out-of-pocket costs at the pharmacy. It was also, predictably, going to push premiums up as insurers recalibrated.
To soften that effect, the Biden administration created what became known as the Part D Premium Stabilization Demonstration. The demonstration, which CMS originally stated could last for at least three years when it was established in 2024, was designed to stabilize stand-alone prescription drug plan premiums and enrollment amid the rollout of changes to the Part D benefit under the Inflation Reduction Act. The demonstration ran for two years – 2025 and 2026 – and it worked by funneling additional federal money directly to insurers to prevent premiums from spiking.
Premium subsidies provided under the demonstration reduced the average monthly PDP premium by $26 in 2025 and $16 in 2026, according to MedPAC, while PDP enrollment increased from 22.8 million in 2024 to 24.9 million. The program also came with a cost. The extra subsidies totaled $9.8 billion in 2025 and 2026.
Why the Administration Says It’s Ending Now
The Centers for Medicare and Medicaid Services said that after examining 2027 plan bids, it determined insurers were now capable of setting prices for their plans on their own, without the program’s financial backing. In plain terms: the market has had two years to adjust, and CMS’s position is that insurers no longer need the training wheels.
CMS Administrator Dr. Mehmet Oz made the announcement on X. On social media, Oz wrote, “The Biden admin gave BILLIONS of taxpayer money DIRECTLY to Big Insurance Companies,” adding, “This is unacceptable.” The argument is that the money was flowing to large corporations rather than directly benefiting the people enrolled in these plans. Administration officials told the Wall Street Journal that had the demonstration continued into 2027, more than half of the funding would have gone to UnitedHealth Group.
That framing is not entirely without merit – the money did go to insurers, not to beneficiaries directly. But it also misses the core cause-and-effect: the subsidy kept premiums lower, which is how the benefit reached enrollees.
The subsidies were expected to last through 2027, but they’re ending a year early. CMS’s own original documentation suggested the program could run for at least three years. Ending it after two – before the market has fully settled into the new Part D structure – is the decision being scrutinized most closely by policy analysts.
What the Numbers Actually Look Like
CMS is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in 2025 to address volatility and variation in standalone premiums. For 2027, CMS bid analysis indicates that Part D plan sponsors had sufficient experience under the redesigned benefit to support their assumptions in developing bids.
The national average monthly bid amount for Part D plans will be set at $296.05 in 2027, approximately a 24% jump from this year. This figure is an enrollment-weighted average of Part D plan bids for the basic drug benefit and is used to calculate the federal subsidy paid to plans. The national base beneficiary premium, which is the starting point for calculating plan-specific premiums, will rise to $41.33 for 2027, up from $38.99 this year.
About half of enrollees will either see a premium increase of less than $10 or a premium decrease, and most will have plans available at $10 or less, according to a Trump administration official. But that framing covers roughly half the enrolled population.
Administration officials told the Journal that roughly 25% of Medicare Part D enrollees are expected to see premiums remain flat or decline in 2027, while about 30% could face monthly increases of less than $10. The remaining 45% are projected to see premium increases largely between $11 and $20 per month.
Ending the subsidies may increase premiums for some by as much as $20 a month, according to KFF, a health policy research nonprofit. KFF’s Juliette Cubanski, deputy director of the Program on Medicare Policy, was direct in her assessment. Without these extra subsidies in place for 2027, some Part D stand-alone drug plan enrollees could face a larger premium increase for drug coverage next year than in recent years, though plan-specific premium amounts are not yet known.
The People Most at Risk
Nearly 25 million people were enrolled in stand-alone Medicare Part D plans in 2026. That population skews heavily toward older adults and people with disabilities, many of whom are on fixed incomes and managing multiple chronic conditions. The $20-a-month ceiling on projected increases is not a comfort when $20 represents a meaningful fraction of what someone has available to spend on medications in a given month.
The end of the demonstration does not eliminate Medicare prescription drug coverage or require beneficiaries to pay the full cost of their medicines. It changes the system used to help stabilize the monthly premiums charged by private insurers offering stand-alone Part D plans. That’s a meaningful distinction, but it doesn’t eliminate the real-world impact for people whose plans price up in the fall.
What Happens Next, and When
CMS will not publish final 2027 premiums and individual plan details until September, meaning beneficiaries do not yet know precisely how much their own coverage will cost. That window between the announcement and the actual numbers is its own kind of stress. Millions of people now know a change is coming but cannot yet calculate what it means for their specific plan, in their specific region, with their specific medications.
The changes are anticipated to happen in 2027 and enrollees will find out the new monthly cost later this fall, administration officials said. Medicare’s annual open enrollment period runs from October 15 through December 7, which means the window to compare plans and make changes will open shortly after the September figures are released. Anyone currently enrolled in a stand-alone Part D plan should treat this year’s open enrollment with more urgency than usual – not because switching plans is always the answer, but because the landscape of premiums will look different enough that it’s worth checking whether your current plan is still the best available option for your situation.
The comparison tools available through Medicare.gov allow enrollees to search plans by zip code and medication list. The September rate release will populate those tools with 2027 pricing. Checking them in October, before the December 7 deadline, gives beneficiaries the best available information to make their decision.
What This Decision Actually Signals
The Medicare Part D program provides prescription drug coverage to about 63 million Americans. The roughly 25 million in stand-alone plans who face potential premium increases are not a rounding error. They are the people the program was designed to protect, and the question of whether ending this particular support helps or hurts them will be answered in individual premium notices this fall, not in press statements in July.
The administration may be right that the demonstration was always meant to be temporary. It may even be right that the market has stabilized enough to function without it. What it cannot do is promise that the people absorbing whatever premium increases materialize next year will find those amounts easy to manage. The space between “less than $10 for most” and “up to $20 for some” is the space between a nuisance and a real problem for someone budgeting medication costs alongside rent.
If you or a family member is enrolled in a stand-alone Medicare Part D plan, mark October 15 on the calendar now. That’s when the numbers will be real, the choices will be in front of you, and the time to act will actually be there.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.